GlassScriptPhysician profile
David B Vasily
NPI 1154327468
$4,066.99
in general payments reported to CMS, 2019-2025
29 companies · $707 in 2025
The $707 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $645 · 2020: $159 · 2021: $509 · 2022: $549 · 2023: $657 · 2024: $842 · 2025: $707.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,116 · Education: $90.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,115.62 |
| Education | $90.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,104.48 | 2019-2025 | Tremfya |
| Abbvie INC. | $845.47 | 2019-2025 | Skyrizi, Rinvoq |
| Amgen INC. | $368.61 | 2020-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $232.38 | 2019-2025 | Nemluvio |
| Merz North America, INC. | $160.24 | 2019-2021 | |
| Genzyme Corporation | $114.96 | 2019-2023 | |
| Leo Pharma INC. | $106.23 | 2019-2025 | Anzupgo, Adbry |
| Ucb, INC. | $98.53 | 2022-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $97.36 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $96.25 | 2023-2024 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $89.07 | 2019-2023 | Dupixent |
| Incyte Corporation | $79.65 | 2022-2024 | Opzelura |
| Genentech USA, INC. | $73.76 | 2019-2024 | Erivedge |
| Lilly USA, LLC | $72.92 | 2022-2025 | Olumiant, Taltz, Ebglyss |
| Mayne Pharma Commercial LLC | $72.63 | 2019-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $63.62 | 2025 | Daxxify |
| Vyne Pharmaceuticals INC. | $50.35 | 2020-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $48.86 | 2019-2024 | Cabtreo |
| Sun Pharmaceutical Industries INC. | $48.50 | 2019-2024 | |
| Prugen, INC. Pharmaceuticals | $39.52 | 2019-2020 | |
| Celgene Corporation | $36.02 | 2019 | |
| Mission Pharmacal Company | $32.33 | 2019-2020 | |
| Allergan, INC. | $30.39 | 2019 | |
| Pfizer INC. | $27.28 | 2020-2022 | |
| Paratek Pharmaceuticals, INC. | $23.82 | 2025 | Nuzyra |
| Biofrontera INC. | $19.60 | 2025 | |
| Promius Pharma LLC | $17.71 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $12.45 | 2022 | |
| Organon LLC | $4.00 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Vasily listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.